GMP cell therapy workflows with additional access to qualified raw materials and gene-modification platforms (lentivirus, RNA) that meet the highest regulatory standards for cell therapy production.
Contact Us
Deep expertise in GMP manufacturing and release of cell therapies including CAR-T, CAR-NK, iPSC and MSC platforms. We also offer access to platform technologies such as lentivirus vector, RNA, and CRISPR gene editing to support gene-modification of target cell populations.
Extensive experience in the GMP manufacturing and release of CAR-T, CAR-NK with access to lentivirus vector and RNA to support gene-modification.
Proven track record using GMP iPSC and MSC workflows to produce stem cell therapies including donor sourcing, technology transfer, process development and GMP readiness of therapies that deploy gene modification technologies.
View GMP iPSC/MSC ServicesA trusted TIL manufacturing services powered by a closed, automated system that ensures consistency, scalability, and potency. With over 10 successful GMP batches, our 03-week TIL production process accelerates your path from research to clinic.
View GMP TIL ServicesDiscover how uBriGene accelerates iPSC-based therapeutics and cell therapies.
Unveil the current manufacturing approaches for LVV and its deployment in cell therapies.
Discover GMP iPSC platform, powered by our efficient RNA-LNP reprogramming cocktail.
Discover AAV manufacturing capabilities, scalable processes, and testing platform.
